Evidence map›Paper›PMID 40166812›Full record

ArticleBrain : a journal of neurology2025

Heterozygous RAB3A variants cause cerebellar ataxia by a partial loss-of-function mechanism.

Holger Hengel, Shabab B Hannan, Selina Reich, Danique Beijer, Johanna Roller, Bernd K Gilsbach, Christian Johannes Gloeckner, Daniel Greene, Dagmar Timmann, Christel Depienne and 25 more

Abstract read
In one paragraph

Article in Brain : a journal of neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Holger HengelDepartment of Neurodegenerative Diseases, Center of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen 72076, Germany.
Shabab B HannanDepartment of Neurodegenerative Diseases, Center of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen 72076, Germany.
Selina ReichDepartment of Neurodegenerative Diseases, Center of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen 72076, Germany.ORCID 0000-0002-2693-4202
Danique BeijerDepartment of Neurodegenerative Diseases, Center of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen 72076, Germany.ORCID 0000-0001-6593-7644
Johanna RollerDepartment of Neurodegenerative Diseases, Center of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen 72076, Germany.
Bernd K GilsbachFunctional Neuroproteomics and Translational Biomarkers in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Tübingen 72076, Germany.
Christian Johannes GloecknerFunctional Neuroproteomics and Translational Biomarkers in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Tübingen 72076, Germany.
Daniel GreeneNIH Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Dagmar TimmannDepartment of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), Essen University Hospital, University of Duisburg-Essen, Essen 45147, Germany.
Christel DepienneInstitute of Human Genetics, University Hospital Essen, University of Duisburg-Essen, Essen 45122, Germany.ORCID 0000-0002-7212-9554
Andrew MumfordSchool of Cellular and Molecular Medicine, University of Bristol, Bristol BS8 1TD, UK.
Mary O'DriscollWest Midlands Regional Clinical Genetics Service, Birmingham Women's Hospital NHS Foundation Trust, Birmingham B15 2TG, UK.
Andrea H NemethOxford Centre for Genomic Medicine, Oxford University Hospitals NHS Foundation Trust, Oxford OX3 7HE, UK.
Julie LundbergDepartment of Pediatrics, Medical Genetics & Genomics, Albany Medical Center, Albany, NY 12208, USA.
Lance H RodanDivision of Genetics and Genomics and Department of Neurology, Boston Children's Hospital, Boston, MA 02115, USA.
Ange-Line BruelInserm UMR1231 GAD, Génétique des Anomalies du Développement, Université de Bourgogne, Dijon 21000, France.
Julian DelanneCentre de Référence Anomalies du Développement et Syndromes Malformatifs, Centre de Génétique, FHU TRANSLAD - CHU Dijon Bourgogne, Dijon 21000, France.
Tine DeconinckCenter of Medical Genetics, University of Antwerp and Antwerp University Hospital, Edegem 2650, Belgium.
Jonathan BaetsFaculty of Medicine and Health Sciences, Translational Neurosciences and Institute Born Bunge, University of Antwerp, Antwerp 2610, Belgium.
Ziv Gan-OrThe Neuro (Montreal Neurological Institute-Hospital), Montreal, Quebec, Canada H3A 2B4.ORCID 0000-0003-0332-234X
Guy RouleauThe Neuro (Montreal Neurological Institute-Hospital), Montreal, Quebec, Canada H3A 2B4.ORCID 0000-0001-8403-1418
Oksana SuchowerskyDepartment of Medicine (Neurology), Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada T6G 2G3.
Mehrdad A EstiarDepartment of Human Genetics, McGill University, Montreal, Quebec, Canada H3A 1Y2.
Stephen ReichNeurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Camilo ToroNIH Undiagnosed Diseases Program, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Stephan ZüchnerDr. John T. Macdonald Foundation, Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of Medicine, Miami, FL 33136, USA.ORCID 0000-0002-8498-5235
Jamilé HazanCenter for Interdisciplinary Research in Biology (CIRB), UMR CNRS 7241/INSERM U1050, Collège de France, Paris 75231, France.
Hjörvar PéturssonInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen 72076, Germany.
Florian HarmuthInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen 72076, Germany.
Claudia BauerInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen 72076, Germany.
Peter BauerInstitute of Medical Genetics and Applied Genomics, University of Tübingen, Tübingen 72076, Germany.
Ernest TurroDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
David LambrightProgram in Molecular Medicine, UMASS Chan Medical School, Worcester, MA 01605, USA.
Ludger SchölsDepartment of Neurodegenerative Diseases, Center of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen 72076, Germany.ORCID 0000-0001-7774-5025
Matthis SynofzikDepartment of Neurodegenerative Diseases, Center of Neurology and Hertie-Institute for Clinical Brain Research, University of Tübingen, Tübingen 72076, Germany.ORCID 0000-0002-2280-7273

Funding

Canadian Institutions for Health Research 260005Canadian Institutions for Health Research RN127580Deutsche Forschungsgemeinschaft 441409627Deutsche Forschungsgemeinschaft 779257Deutsche Forschungsgemeinschaft 825575Deutsche Forschungsgemeinschaft 8803/1-1DFG Research Infrastructure West German Genome Center 407493903DFG Research Infrastructure West German Genome Center 423957469DFG Research Infrastructure West German Genome Center 458099954DFG Research Infrastructure West German Genome Center R01HL161365DFG Research Infrastructure West German Genome Center R03HD111492Fonds de recherche du Québec
6 · The paper itself

Abstract

RAB3A encodes a small GTP-binding protein that is abundant in brain synaptic vesicles and crucial for the release of neurotransmitters and synaptic plasticity. Here, we identified RAB3A as a candidate gene for autosomal dominant cerebellar ataxia by two independent approaches: linkage in a large dominant ataxia family and, in parallel, an untargeted computational genetic association approach, analysing the 100 000 Genomes Project datasets. To validate the role of RAB3A in ataxia, we next screened large rare disease databases for rare heterozygous RAB3A variants in probands with ataxia features. In total, we identified 18 individuals from 10 unrelated families all sharing a cerebellar ataxia phenotype. Notably, 9 of the 10 families carried a recurrent variant in RAB3A, p.Arg83Trp, including one de novo occurrence. In addition, our screening revealed three families with a neurodevelopmental phenotype and three unique RAB3A variants, which were either de novo or loss-of-function variants. In line with the different RAB3A variant types, protein domains and predicted functional consequences, a comprehensive set of complementary methods was used to characterize the identified variants functionally. As expected, GTPase-activating protein (GAP)-dependent GTP hydrolysis was reduced for those two missense variants located in the GAP-binding domain of RAB3A (Arg83Trp and Tyr91Cys). In a Drosophila Rab3 loss-of-function model, these two missense variants also failed to rescue a synaptic phenotype. Overexpression of Rab3 variants in Drosophila wild-type background did not cause an obvious phenotype, making a dominant negative effect of these variants unlikely. Lastly, exploring interactors of RAB3A variants by using co-immunoprecipitation and mass spectrometry showed differential changes in variant-specific interactions with known RAB3A key regulatory and effector proteins. In sum, our results establish RAB3A as a neurological disease gene. It represents an autosomal dominant gene for cerebellar ataxia with different variants associated with disease, including the frequent reoccurring variant p.Arg83Trp. Our study sheds light on the variant-specific interactome of RAB3A. Finally, we suggest an association of RAB3A with a neurodevelopmental phenotype, as reported for variants in several RAB3A interaction partners and as seen in Rab3A-deficent mice, although this possible association warrants further investigation by future studies.

Indexed as

Cerebellar AtaxiaLoss of Function Mutationrab3A GTP-Binding ProteinAdultAnimalsFemaleHeterozygoteHumansMaleMiddle AgedPedigreePhenotyperab3A GTP-Binding ProteinBayesian statistical genetic associationgenome sequencingGTPaseneurodevelopmental disorderneurogenetic diseaseRareservoir

Identifiers

PMID40166812
PMCPMC12316009

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.